Skip to main content

Table 2 Type and risks of clinical events included in the model (reported per 100 patient/years)

From: Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina

Events

Apixaban

Warfarin

Source

Ischemic stroke risk by CHADS2

  

[15]

Mean

0,962

1,064

 

CHADS2 score 0

0,521

0,458

 

CHADS2 score 1

0,521

0,458

 

CHADS2 score 2

0,950

0,934

 

CHADS2 score 3

1,534

1,944

 

CHADS2 score 4

1,534

1,944

 

CHADS2 score 5

1,534

1,944

 

CHADS2 score 6

1,534

1,944

 

Systemic embolism

0.090

0.100

[12]

Hemorrhagic stroke and Intracranial Hemorrhage

0.330

0.800

[12]

Other major bleeding

1.790

2.270

[12]

Clinically Relevant Non-Major Bleeding

2.083

2.995

[15]

Myocardial Infarction

0,530

0,610

[12]

Other hospitalizations due to cardiovascular disease

10.460

10.460

[15]

Recurrent ischemic stroke

4.103

4.103

[43]

Recurrent hemorrhagic stroke

3.00

3.00

[43]